Vent, this is big news out here right now in the home of Boston Scientific and I read about it in the paper every day. Boston scientific really leapt forward in 2004 with the Taxus stent increasing sales by $2 billion. Let me again recap so everyone is on the same page:
In March 2 studies were reported at the ACC meeting. The BASKET trial looked at 18 month data of bare vs coated stents and the Camenzind study was a meta-anaylsis of 3 year data. BASKET showed an increase in death not significant with coated stents, the meta-analysis showed a significant increase in death at 3 years. These are late restenoses when people are off of Plavix, as they would normally stop it after 3-6 months, or up to a year if no increased bleeding risk with an eluting stent. Now the FDA is involved and just announced a meeting in December with the 2 stent makers, so this is still up in the air.
So now we've got a guy that a year ago would come to us and we (or someone) could say "let's just stop the plavix, you've been on it for a year and have an eluting stent, no reason to continue". Now it would seem prudent for this guy to be on prolonged, maybe lifelong Plavix.
Here is a link:
http://heartdisease.about.com/od/angioplastystents/a/drgstnt4.htm
Apparently in light of all of this, some cardiologists are saying the the Plavix can never be stopped under any circumstances for any procedure.
As far as our role, I would think that ortho has to decide if they can operate and risk intra-articular hematoma on plavix. It will change what we do if they think they can obviously if we considered a spinal. I think the cardiologist has to call the shots on this one after a frank discussion of the risks and current controversies with the patient.
Now for some fun stuff and where to put your money:
On July 18, 2006, the New York Times, reported that Bristol-Myers had already seen a double-digit sales increase for Plavix in the US this year, up 26% to $850 million.